Response to Whitely: A caution from the coalface

Australian and New Zealand Journal of Psychiatry

Volumn 46, Issue 5, 2012, Pages 404-406

  Levy, Florence ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; CARDIOVASCULAR EFFECT; DYSPNEA; EDUCATION; HEALTH CARE PLANNING; HEART PALPITATION; NOTE; TACHYCARDIA; TREATMENT DURATION; CLINICAL PRACTICE; HUMAN;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84865293844     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867412444108     Document Type: Note

References (14)

1. Bussing R, Zima B, Mason B, et al. Use and persistence of pharmacotherapy for elementary school students with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. 2005 ; 2005: 78-87 (Pubitemid 40365917)
2. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine. 2011 ; 365: 1896-1904
3. Habel LA, Cooper WO, Sox CM. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. Journal of the American Medical Association. 2011 ; 306: 2673-2683
4. Hammerness PG, Surman CB, Chilton A. Adult Attention-Deficit/ Hyperactivity Disorder treatment and cardiocascular implications. Current Psychiatry Reports. 2011 ; 13: 357-363
5. Hinshaw SP, Scheffler RM, Fulton B, et al. International variation in treatment procedures for attention-deficit/hyperactivity disorder: Social context and recent trends. Psychiatric Services. 2011 ; 62: 459-464
6. Kratochivil CJ. ADHD Pharmacotherapy: Rates of stimulant use and cardiovascular risk. American Journal of Psychiatry. 2012 ; 169: 112-114
7. Kroutil LA, Van Brunt DL, Herman-Stahl MA, et al. Nonmedical use of prescription stimulants in the United States. Drug and Alcohol Dependency. 2006 ; 84: 135-143 (Pubitemid 44160579)
8. LevyF (submitted) Stimulant Side effects and Inverted-U: Implications for ADHD Guidelines.
9. Levy F, Young D, Mitchell P, et al.. Poster presentation at Australasian Society for Psychiatric Research ; 2010 Sydney ; 2010..
10. Prosser B, Reid R. Changes in use of psychostimulant medication for ADHD in South Australia (1990-2006). Australian and New Zealand Journal of Psychiatry. 2009 ; 43: 340-347
11. Schelleman H, Bilker WB, Kimmel SE, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011 ; 127: 1102-1110
12. Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. American Journal of Psychiatry. 2012 ; 169: 178-185
13. Whitely M Speed Up and Sit Still. Telethon Institute for Child Health Research, The Raine Study. Crawley: UWA Publishing ; 2010 :
14. Wilens TE, Adler LA, Adams MD, et al. Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature. Journal of the American Academy of Child & Adolescent Psychiatry. 2008 ; 47: 21-31